Padcev (enfortumab vedotin-ejfv) is a Nectin-4-directed antibody and microtubule inhibitor conjugate used:

as a single agent for the treatment of adults with locally advanced or metastatic urothelial cancer who have previously been treated with programmed death receptor-1 (PD-1) or programmed death-ligand 1 (PD-L1) inhibitor and platinum-containing chemotherapy, or are ineligible for cisplatin-containing chemotherapy and have previously treated with one or more prior lines of therapy.
along with medicine pembrolizumab to treat adults with locally advanced or metastatic urothelial cancer (mUC) who are not eligible for cisplatin-containing chemotherapy.